Ascentage Pharma announced that the Center for Drug Evaluation of the China National Medical Products Administration has approved a registrational pivotal Phase III study of olverembatinib, Ascentage Pharma’s lead drug candidate, in combination with chemotherapy comparing imatinib in combination with chemotherapy for treatment of patients with naïve Philadelphia chromosome-positive acute lymphoblastic leukemia.
